• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark

    Reed-Lane Facility Virtual Tour
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Data Management Trends

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Syngene

    PCI Pharma Services

    Reed-Lane

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    Cytovance Biologics

    Reed-Lane

    Alcami

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    02 Roche

    ...

    Related CONTENT
    • Strata Oncology Unveils Strata PATH Trial
    • Spark Therapeutics Appoints CTO
    • BioDuro-Sundia Appoints CEO
    • Financial Report: Roche
    • Affimed, Roche Explore AFM24, Tecentriq Combo
    07.20.18
    Headquarters: Basel, Switzerland
    twitter.com/Roche
    www.roche.com

    Headcount: 93,734 
    Year Established: 1896
    Total Revenues: $54,591  (+5%)
    Pharma Revenues: $42,219  (+5%)
    Net Income: $9,039  (-9%)
    R&D: $11,566  (+2%)

    TOP SELLING DRUGS  
    Drug Indication 2017 Sales (+/-%)
    MabThera/Rituxan cancer, rheumatoid $7,506 1%
    Herceptin arthritis $7,506 1%
    Avastin breast cancer $6,794 2%
    Perjeta breast cancer $2,231 23%
    Actemra/RoActemra rheumatoid arthritis $1,957 18%
    Xolair asthma $1,770 20%
    Lucentis macular degeneraton $1,436 4%
    Activase/TNKase acute myocardial infarction $1,238 14%
    Kadcyla breast cancer $928 14%
    Esbriet pulmonary fibrosis $883 13%
    Tarceva lung cancer $856 -14%
           

    Roche Group’s pharmaceutical business reported solid overall results in 2017. Revenue grew 5% to $42.2 billion from $38.3 billion a year ago—good enough to move into the number two spot from four last year.

    Pharmaceutical sales growth contributed $1.4 billion of new sales, representing 65% of the division’s growth. In oncology, HER2 franchise sales increased by 7% to $10.1 billion, led by Perjeta. MabThera/Rituxan sales were $7.5 billion, a growth of 1% globally, despite sales in Europe being 11% lower following biosimilar entry. Sales of Avastin were $6.7 billion, a decline of 2% due to competitive pressure. Sales in immunology grew to $7.6 billion, with Xolair and Actemra/RoActemra increasing by 16% and 14% respectively. Sales of Tamiflu fell by 33% due to competition from generics in the U.S. market.

    During the year, the Swiss drug maker scored a major victory when FDA approved Ocrevus, a new multiple sclerosis (MS) drug from Roche’s Genentech unit that is poised to make a major impact on the market for MS and could prove to be a blockbuster. Since its launch, more than 30,000 prescriptions have been written and sales estimates for 2022 are projected to be more than $4 billion.

    To say the FDA’s approval of the drug back in March 2017 was big news in the MS world is an understatement. Why is Ocrevus touted for being the leading new drug approval from the class of 2017? Well, there are approximately 15 other medications—known as disease-modifying treatments, or DMTs — for MS, but they only treat the most common form of MS, called relapsing-remitting multiple sclerosis (RRMS).

    Ocrevus is groundbreaking because, while it has been very effective for RRMS, it is also the first medication approved to treat primary-progressive multiple sclerosis (PPMS), a less-common form of the disease. According to the National Multiple Sclerosis Society, 85 percent of people with MS have RRMS, while 10 to 15 percent are diagnosed with PPMS.

    Roche was awarded several other new drug approvals during the year, some of which are highlighted here. First, FDA gave the green light to cancer drug Perjeta, in combination with Herceptin and chemotherapy—the Perjeta-based regimen—for adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence.

    The drug enforcer also approved Roche’s Gazyva for previously untreated advanced follicular lymphoma. The approval marks the first treatment option to demonstrate superior progression-free survival over standard-of-care Rituxan-based therapy.

    Hemlibra for haemophilia A with inhibitors was approved and is the first new medicine in nearly 20 years to treat people with haemophilia A with inhibitors. The drug was shown to substantially reduced bleeds in adults and children.

    FDA also approved Zelboraf for Erdheim-Chester disease with BRAF V600 mutation. Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease (ECD), a rare blood disease.
    Alecensa also was approved as a first-line treatment for people with specific type of lung cancer. Approval was based on Phase III results that showed Alecensa extended the average time that people lived without their disease worsening compared to crizotinib.

    Actemra/RoActemra was approved for the treatment of CAR T cell-induced cytokine release syndrome. Actemra/RoActemra is the first FDA-approved treatment for severe or life-threatening cytokine release syndrome induced by CAR T cell therapy. This marks the seventh FDA approval for Actemra/RoActemra since its U.S. launch in 2010
    Lasty, FDA ok’d Roche’s Lucentis for diabetic retinopathy, the leading cause of blindness among working age adults in the U.S. It is the first and only medicine approved to treat all forms of diabetic retinopathy on the market.

    Billion dollar deals
    At the start of 2018 Roche made a couple of major M&A transactions. First, to boost its cancer pipeline, it paid $1.7 billion to acquire Ignyta, Inc., a U.S. based pharmaceutical company focused on developing cancer therapies. The acquisition expands Roche’s oncology portfolio globally. Ignyta is responsible for the ongoing study of entrectinib, its most advanced cancer drug being studied in a range of solid tumor types. The company also has a portfolio of drugs in early stage development that use gene therapy to kill the underlying diseases that drive cancer tumor growth. Ignyta employs an integrated “Rx/Dx” approach that combines precision medicines (Rx) and in-house molecular diagnostics (Dx) to both identify and target hard-to-treat cancers in hard-to-find patients.

    Second, Roche continued its push into the personalized healthcare space with the purchase of Flatiron Health in a deal worth $1.9 billion. Flatiron is a healthcare technology and services company focused on accelerating cancer research and improving patient care. They develop oncology-specific electronic health record (EHR) systems, most notably an information exchange platform which allows researchers to access and learn from patient records. The company’s message is that large amounts of data could be used to speed up and, in some cases, replace certain clinical trials where patients are randomly assigned to a specific treatment.

    Roche’s chief executive of its pharma division, Dan O’Day said the deal marks an important step in its personalized healthcare strategy for Roche. “We believe that regulatory-grade real-world evidence is a key ingredient to accelerate the development of, and access to, new cancer treatments,” he said. “As a leading technology company in oncology, Flatiron Health is best positioned to provide the technology and data analytics infrastructure needed not only for Roche but for oncology research and development efforts across the entire industry.” Previously, Roche led a Series C funding round for Flatiron in 2016.

    In other precision medicine news, during the year Syapse and Roche entered into a multi-year strategic collaboration to help make precision medicine available to more cancer patients. The two companies unveiled plans to work jointly to develop software products and analytics solutions to provide the tools and insights healthcare providers need to practice precision medicine at scale, with the goal of improving patient outcomes. Roche is funding the development of these products, which aim to benefit oncologists, health systems, and stakeholders including payers. Syapse will develop and deploy these new products to the precision medicine ecosystem, beginning with its existing healthcare provider network.

    The companies will initially focus on four product programs: real-world evidence, so that physicians can make better care decisions; better understanding the health economics impact and patient outcomes of precision medicine; advancing electronic patient-reported outcomes to understand precision medicine’s effect on health-related quality of life; and accelerating clinical trial enrollment by matching patients to precision trials at the point of care. Roche and Syapse will also collaborate on automated methods for measuring real-world outcomes.

    Research Collaborations
    On the collaboration front, during the year Roche teamed up with Confo Therapeutics for the discovery, development and commercialization of novel, small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) for the treatment of neurological and developmental disorders. Roche gains exclusive rights to the compounds resulting from the collaboration and will be responsible for their development, manufacturing and commercialization. The financial terms included an upfront payment, preclinical milestones and research funding to Confo Therapeutics totaling more than $7 million over the first 30 month period with up to $96.3 million in milestone payments.

    Roche’s Genentech unit was also very active in research tie-ups. At the very end of 2016 Genentech extended its exclusivity period for the research collaboration and license agreement with Phylogica Ltd. to discover novel antibiotics using Phylogica’s Phylomer drug discovery platform, including its proprietary cell penetrating peptide discovery technology.

    At the beginning of 2017 Corvus Pharmaceuticals expanded its clinical collaboration with Genentech for CPI-444 in combination with atezolizumab (Tecentriq) to be evaluated in a Phase Ib/II clinical study as second-line therapy in non-small cell lung cancer (NSCLC). The study will be part of Morpheus, Genentech’s novel cancer immunotherapy platform established to develop immunotherapy combination therapies more rapidly and efficiently. CPI-444, Corvus’ lead product, is a selective and potent inhibitor of the adenosine A2A receptor. Atezolizumab, developed by Genentech, is a monoclonal antibody designed to target and bind to a protein called PD-L1 (programmed death ligand-1).

    With Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, Genentech expanded an existing license agreement for the development of new therapeutics using Arvinas’ Protac technology. The multi-year strategic collaboration initiated in October 2015 will now encompass additional disease targets. The Protac platform removes target proteins directly rather than inhibiting them. This differs from small molecule inhibitors, which often result in toxic side effects and eventual drug resistance. Under the revised terms of the agreement, Arvinas is now eligible to receive development and commercialization milestone payments in excess of $650 million. In addition, they are also able to receive tiered-royalties on sales of products resulting from the license agreement.

    Genentech and Biothera Pharmaceuticals entered into a clinical trial collaboration agreement to assess the safety and efficacy of Biothera’s Imprime PGG in combination with Genentech’s atezolizumab, an anti-PD-L1 antibody, and bevacizumab, an anti-VEGF antibody, to treat patients with metastatic colorectal cancer. Genentech will conduct the multicenter trial, which will enroll approximately 40 patients in the initial phase of the study. Under the agreement, researchers will evaluate the potential of Imprime PGG, atezolizumab and bevacizumab to increase overall patient responses.

    At the start of 2018, Genentech and Syndax Pharmaceuticals formed a new clinical collaboration to evaluate the combination of Syndax’s entinostat, an oral, small molecule, class I HDAC inhibitor, and Genentech’s programmed cell death ligand 1 (PD-L1) blocking antibody, atezolizumab (Tecentriq), in patients with second-line hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+, HER2-) metastatic breast cancer. The planned Phase Ib/II, open-label, multicenter, randomized trial will enroll patients with metastatic HR+, HER2- breast cancer who have experienced disease progression during or following first-line therapy. Genentech will be responsible for conducting the trial. 
    Related Searches
    • small molecule inhibitors
    • data analytics
    • it
    • analytics
    Suggested For You
    Strata Oncology Unveils Strata PATH Trial Strata Oncology Unveils Strata PATH Trial
    Spark Therapeutics Appoints CTO Spark Therapeutics Appoints CTO
    BioDuro-Sundia Appoints CEO BioDuro-Sundia Appoints CEO
    Financial Report: Roche Financial Report: Roche
    Affimed, Roche Explore AFM24, Tecentriq Combo Affimed, Roche Explore AFM24, Tecentriq Combo
    Imcyse, Pfizer Enter Autoimmune Research Alliance Imcyse, Pfizer Enter Autoimmune Research Alliance
    Caprion-HistoGeneX Rebrands as CellCarta Caprion-HistoGeneX Rebrands as CellCarta
    Precision Medicine Group Acquires Project Farma Precision Medicine Group Acquires Project Farma
    Data, Analytics & AI for Precision Medicine Data, Analytics & AI for Precision Medicine
    Samsung Biologics Names John Rim as President and CEO Samsung Biologics Names John Rim as President and CEO
    AstraZeneca to Acquire Alexion in $39B Deal AstraZeneca to Acquire Alexion in $39B Deal
    ARCA Biopharma’s AB201 for COVID-19 Gets Fast Track  ARCA Biopharma’s AB201 for COVID-19 Gets Fast Track
    Decentralized Trials Fuel AI Revolution in Clinical Research Decentralized Trials Fuel AI Revolution in Clinical Research
    Opportunities in Synthetic Biology Opportunities in Synthetic Biology
    Lead Pharma and Roche Enter Collaboration & License Agreement Lead Pharma and Roche Enter Collaboration & License Agreement

    Related Top Companies Report

    • 25 CSL Behring

      25 CSL Behring

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 22 Astellas

      22 Astellas

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 21 Biogen

      21 Biogen

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20


    • 12 Amgen

      12 Amgen

      ...
      Tim Wright, Editor, Contract Pharma 07.20.20

    • 13 Gilead Sciences

      13 Gilead Sciences

      ...
      Kristin Brooks, Managing Editor 07.15.20

    • 10 Bristol-Myers Squibb

      10 Bristol-Myers Squibb

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.15.20


    • 03 Novartis

      03 Novartis

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 02 Roche

      02 Roche

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 09 Takeda

      09 Takeda

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • 01 Pfizer, Inc.

      01 Pfizer, Inc.

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • The 2020 Top 25 Pharma and Biopharma Companies

      The 2020 Top 25 Pharma and Biopharma Companies

      Top 25 Pharma and Biopharma Companies (Based on 2019 Pharma/Biopharma Sales, in $U.S. Millions)
      Contract Pharma Staff 07.15.20

    • 08 GlaxoSmithKline

      08 GlaxoSmithKline

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • 07 AbbVie

      07 AbbVie

      ...
      Kristin Brooks , Managing Editor, Contract Pharma 07.15.20

    • 06 Sanofi

      06 Sanofi

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 05 Merck

      05 Merck

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    Trending
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Reed-Lane Facility Virtual Tour
    Breaking News
    • AGC Biologics Expands Cell and Gene Facility in Italy
    • Celonic to Boost Cell & Gene Therapy Production
    • Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    • Aptamer Extends Collaboration with AstraZeneca
    • Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Thymoquinone Inhibits Viral Infection in In Vitro Settings, New Study Finds
    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Coatings World

    Latest Breaking News From Coatings World

    Sherwin-Williams Announces Resignation of President and COO
    Ashland Completes Expansion and Relocation of Viatel Bioresorbable Polymers Manufacturing Facility
    Evonik Receives Sustainability Award from EcVadis
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex CFO Announces Retirement
    New AI-Based Tool Developed for Coronary Artery Analysis, Intervention Planning
    First Reported Use of Pulse Biosciences' CellFX System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    AGC Biologics Expands Cell and Gene Facility in Italy
    Celonic to Boost Cell & Gene Therapy Production
    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Ulta Beauty Opens in Herald Square
    Elizabeth Arden Taps Sui He as Global Brand Ambassador
    Natura &Co Outperforms the Global Market in Q4 2020
    Happi

    Latest Breaking News From Happi

    What You're Reading on Happi.com
    Indie Beauty Innovators Wanted
    Cosmetic Chemists Seek Mentors
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Arjobex America welcomes Maggie Naberezny to sales team
    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Colfax Decides to Divide Its Businesses
    Stryker Corp.'s 2020 Sales Slip 3.6 Percent
    Bioventus Appoints Managing Director, China and Asia Pacific
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login